Roles of SIRT1 in leukemogenesis

Current Opinion in Hematology

Volumn 20, Issue 4, 2013, Pages 308-313

  Chen, Wenyong ^a   Bhatia, Ravi ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Division of Hematopoietic Stem Cell and Leukemia Research   (United States)

Author keywords

Acquired resistance; BCR ABL; Chronic myeloid leukemia; Leukemic stem cells; SIRT1

Indexed keywords

ABELSON KINASE; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SIRTUIN 1; STAT5 PROTEIN;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; BLAST CELL CRISIS; BONE MARROW CELL; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT; DEACETYLATION; DNA END JOINING REPAIR; EMBRYONIC STEM CELL; EPITHELIUM CELL; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; KNOCKOUT GENE; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMOGENESIS; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STEM CELL;

CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID; PROTEIN KINASE INHIBITORS; SIRTUIN 1;

EID: 84880214905     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328360ab64     Document Type: Review

References (40)

1. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 2000; 273:793-798.
2. Imai S, Armstrong CM, Kaeberlein M, et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403:795-800.
3. Vaquero A, Scher M, Lee D, et al. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 2004; 16:93-105.
4. Vaquero A. The conserved role of sirtuins in chromatin regulation. Int J Dev Biol 2009; 53:303-322.
5. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012; 13:225-238.
6. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007; 26:5489-5504.
7. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7:441-453.
8. Yuan H, Wang Z, Li L, et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 2012; 119:1904-1914. This is the first article providing genetic evidence that loss of SIRT1 inhibits BCR-ABL-mediated leukemogenesis, and also showing BCR-ABL activation of SIRT1 in part through STAT5.
9. Li L, Wang L, Wang Z, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012; 21:266-281. This is the first article showing that SIRT1 is crucial for resistance of CML leukemic stem cells to imatinib by deacetylating and inactivating p53.
10. Leko V, Varnum-Finney B, Li H, et al. SIRT1 is dispensable for function of hematopoietic stem cells in adult mice. Blood 2012; 119:1856-1860. This article provides detailed analysis of hematological phenotypes of adult SIRT1 knockout mice.
11. Narala SR, Allsopp RC, Wells TB, et al. SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol Biol Cell 2008; 19:1210-1219.
12. Ou X, Chae HD, Wang RH, et al. SIRT1 deficiency compromises mouse embryonic stem cell hematopoietic differentiation, and embryonic and adult hematopoiesis in the mouse. Blood 2011; 117:440-450.
13. McBurney MW, Yang X, Jardine K, et al. The absence of SIR2alpha protein has no effect on global gene silencing in mouse embryonic stem cells. Mol Cancer Res 2003; 1:402-409.
14. Han MK, Song EK, Guo Y, et al. SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell 2008; 2:241-251.
15. Matsui K, Ezoe S, Oritani K, et al. NAD-dependent histone deacetylase, SIRT1, plays essential roles in the maintenance of hematopoietic stem cells. Biochem Biophys Res Commun 2012; 418:811-817.
16. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008; 14:312-323.
17. Wang Z, ChenWY. Emerging roles of SIRT1 in cancer drug resistance. Genes Cancer 2013. doi: 10.1177/1947601912473826. [Epub ahead of print]
18. Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene 2007; 26:6738-6749.
19. Bradbury CA, Khanim FL, Hayden R, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005; 19:1751-1759.
20. Hennighausen L, RobinsonGW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 2008; 22:711-721.
21. Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 2008; 3:e2020.
22. Oberdoerffer P, Michan S, McVay M, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008; 135:907-918.
23. Herranz D, Munoz-Martin M, Canamero M, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 2010; 1:3.
24. Herranz D, Maraver A, Canamero M, et al. SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency. Oncogene 2012. doi:10.1038/ onc.2012.407. [Epub ahead of print]
25. O'Hare T, ZabriskieMS, Eiring AM, et al. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12:513-526.
26. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011; 118:5565-5572.
27. Konig H, Holtz M, Modi H, et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008; 22:748-755.
28. Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13:454-463.
29. Cheok CF, Verma CS, Baselga J, et al. Translating p53 into the clinic. Nat Rev Clin Oncol 2011; 8:25-37.
30. Wang Z, Yuan H, Roth M, et al. SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene 2013; 32:589-598. This is the first article showing that SIRT1 promotes acquisition of BCR-ABL mutations for CML-acquired resistance to tyrosine kinase inhibitors.
31. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
32. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-880.
33. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117-125.
34. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI- 571 inhibition of abelson tyrosine kinase. Science 2000; 289:1938-1942.
35. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006; 312:1175-1178.
36. Yuan H, Wang Z, Gao C, et al. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem 2010; 285: 5085-5096.
37. Nowicki MO, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104:3746-3753.
38. Slupianek A, Nowicki MO, Koptyra M, et al. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair (Amst) 2006; 5:243-250.
39. Chen W. Accelerating cancer evolution: a dark side of SIRT1 in genome maintenance. Oncotarget 2012; 3:363-364.
40. Chakraborty S, Stark JM, Sun CL, et al. Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining. Blood 2012; 119:6187-6197.